EAM
STOK icon

Exome Asset Management’s Stoke Therapeutics STOK Stock Holding History

Exome Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-113,096
Closed -$1.25M – 81
2024
Q4 		$1.25M Sell
113,096
-63,504
-36% -$780K 0.94% 38
2024
Q3 		$2.17M Buy
+176,600
New +$2.5M 1.47% 32

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Exome Asset Management's STOK Position: Q1 2025 in Review

Exome Asset Management sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 113,096 shares — an estimated $1.25M sold.

Exome Asset Management first reported a position in STOK in Q3 2024 and held it in 2 quarters. The position peaked at $2.17M in Q3 2024. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

  • Exome Asset Management reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 113,096 Stoke Therapeutics shares in Q1 2025, an estimated $1.25M.
  • Exome Asset Management first reported a position in Stoke Therapeutics in Q3 2024 and held it in 2 quarters.
  • Exome Asset Management's Stoke Therapeutics position peaked at $2.17M in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.